+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report



Intersurgical interval increased with use of quadrivalent human papillomavirus vaccine (Gardasil) in a pediatric patient with recurrent respiratory papillomatosis: A case report



International Journal of Pediatric Otorhinolaryngology 91: 166-169



This is a case of a 4 year old female with recalcitrant recurrent respiratory papillomatosis with decreasing intersurgical interval that had improvement in clinical course after administration of the quadrivalent HPV vaccine.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 058143587

Download citation: RISBibTeXText

PMID: 27863633

DOI: 10.1016/j.ijporl.2016.10.032


Related references

Treatment With Quadrivalent Human Papillomavirus Vaccine for Juvenile-Onset Recurrent Respiratory Papillomatosis: Case Report and Review of the Literature. Journal of the Pediatric Infectious Diseases Society 6(4): 380-385, 2017

The use of the quadrivalent human papillomavirus vaccine (gardasil) as adjuvant therapy in the treatment of recurrent respiratory papilloma. Journal of Voice 29(2): 223-229, 2016

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil): profile report. Biodrugs 20(5): 313-316, 2006

Human Papillomavirus Quadrivalent (types 6,11, 16,18) Recombinant Vaccine (Gardasil): Profile Report. BioDrugs 20(5): 313-316, 2006

Juvenile-Onset Recurrent Respiratory Papillomatosis: The Benefits of Quadrivalent Human Papillomavirus Vaccination Continue to Accrue. Journal of Infectious Diseases 217(2): 177-178, 2017

The potential health and economic benefits of preventing recurrent respiratory papillomatosis through quadrivalent human papillomavirus vaccination. Vaccine 26(35): 4513-4518, 2008

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil). Therapeutics and Clinical Risk Management 4(1): 65-70, 2008

The efficacy and safety of the quadrivalent human papillomavirus 6/11/16/18 vaccine gardasil. Journal of Adolescent Health 49(5): 467-475, 2012

Human papillomavirus quadrivalent (types 6, 11, 16, 18) recombinant vaccine (Gardasil). Drugs 66(9): 1263-71; Discussion 1272-3, 2006

Recurrent respiratory papillomatosis in a pediatric patient: case report. Revista Chilena de Pediatria 88(3): 393-397, 2018

Efficacy of quadrivalent human papillomavirus (types 6, 11, 16 and 18) vaccine (GARDASIL) in Japanese women aged 18-26 years. Cancer Science 104(4): 465-472, 2013

Recurrent laryngeal papillomatosis with oesophageal involvement in a 2 year old boy: successful treatment with the quadrivalent human papillomatosis vaccine. International Journal of Pediatric Otorhinolaryngology 79(2): 262-266, 2015

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard. Clinical Medicine Insights. Case Reports 3: 69-71, 2010

Aggressive human papillomavirus (HPV)-11-related sinonasal inverted papilloma in an HIV-infected patient and the quadrivalent HPV vaccine: a case report. Aids 29(17): 2366-2368, 2016

FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). Mmwr. Morbidity and Mortality Weekly Report 59(20): 630-632, 2010